Bamlanivimab and Etesevimab Combination Infusion Treatment
MAHEC has received a supply of the new investigational COVID-19 monoclonal antibody treatments, Bamlanivimab (BAM) and Etesevimab (ETE). This treatment may lessen the severity of illness in high risk, mild to moderately ill people infected with COVID-19 and reduce hospitalizations.
Information about Bamlanivimab and Etesevimabcan be reviewed in the following fact sheets:
- PHE fact sheet for healthcare providers - fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab
- PHE fact sheet for patients and caregivers - fact Sheet for Patients, Parents and Caregivers: Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab for Coronavirus Disease 2019 (COVID-19)
- What to expect during your treatment at MAHEC - this fact sheet will answer many questions patients may have.
Patients must be referred for treatment by a healthcare provider.
MAHEC will only be able to administer Bamlanivimab and Etesevimab to patients 12 years and older who are in first 10 days of symptoms at time of treatment.
Internal referrals can be made by sending a patient message to FM Acute Care Infusion.
External referrals can be made by filling out the referral form located here.
Infusions will take place on the MAHEC Biltmore campus Monday through Friday.
All patients will be contacted by phone the day of or the day prior to infusion AND the day after infusion.
All patients will be encouraged to see their primary care provider by telehealth within 3-7 days of the infusion treatment. Patients who do not have a primary care provider will be referred to MAHEC Internal Medicine for a follow up visit by telehealth.
Patient treatment criteria:
Bamlanivimab and Etesevimab is a treatment option for people with documented COVID-19 infection who meet the following criteria:
|Patients with one of the following||Patients ≥55 years of age with one of the following||Patients 12 – 17 years of age with one of the following:|